Search for: All records

Autophagy, as an intracellular degradation system, plays a critical role in plant immunity. However, the involvement of autophagy in the plant immune system and its function in plant nematode resistance are largely unknown. Here, we show that root-knot nematode (RKN;Meloidogyne incognita) infection induces autophagy in tomato (Solanum lycopersicum) and differentatgmutants exhibit high sensitivity to RKNs. The jasmonate (JA) signaling negative regulators JASMONATE-ASSOCIATED MYC2-LIKE 1 (JAM1), JAM2 and JAM3 interact with ATG8s via an ATG8-interacting motif (AIM), and JAM1 is degraded by autophagy during RKN infection. JAM1 impairs the formation of a transcriptional activation complex between ETHYLENE RESPONSE FACTOR 1 (ERF1) and MEDIATOR 25 (MED25) and interferes with transcriptional regulation of JA-mediated defense-related genes by ERF1. Furthermore, ERF1 acts in a positive feedback loop and regulates autophagy activity by transcriptionally activatingATGexpression in response to RKN infection. Therefore, autophagy promotes JA-mediated defense against RKNs via forming a positive feedback circuit in the degradation of JAMs and transcriptional activation by ERF1.

 

Abstract Biomarkers predictive of drug-specific outcomes are important tools for personalized medicine. In this study, we present an integrative analysis to identify miRNAs that are predictive of drug-specific survival outcome in cancer. Using the clinical data from TCGA, we defined subsets of cancer patients who suffered from the same cancer and received the same drug treatment, which we call cancer-drug groups. We then used the miRNA expression data in TCGA to evaluate each miRNA’s ability to predict the survival outcome of patients in each cancer-drug group. As a result, the identified miRNAs are predictive of survival outcomes in a cancer-specific and drug-specific manner. Notably, most of the drug-specific miRNA survival markers and their target genes showed consistency in terms of correlations in their expression and their correlations with survival. Some of the identified miRNAs were supported by published literature in contexts of various cancers. We explored several additional breast cancer datasets that provided miRNA expression and survival data, and showed that our drug-specific miRNA survival markers for breast cancer were able to effectively stratify the prognosis of patients in those additional datasets. Together, this analysis revealed drug-specific miRNA markers for cancer survival, which can be promising tools toward personalized medicine. 

This paper presents Kage: a system that protects the control data of both application and kernel code on microcontroller-based embedded systems. Kage consists of a Kage-compliant embedded OS that stores all control data in separate memory regions from untrusted data, a compiler that transforms code to protect these memory regions efficiently and to add forward-edge control-flow integrity checks, and a secure API that allows safe updates to the protected data. We implemented Kage as an extension to FreeRTOS, an embedded real-time operating system. We evaluated Kage’s performance using the CoreMark benchmark. Kage incurred a 5.2% average run-time overhead and 49.8% code size overhead. Furthermore, the code size overhead was only 14.2% when compared to baseline FreeRTOS with the MPU enabled. We also evaluated Kage’s security guarantees by measuring and analyzing reachable code-reuse gadgets. Compared to FreeRTOS, Kage reduces the number of reachable gadgets from 2,276 to 27, and the remaining 27 gadgets cannot be stitched together to launch a practical attack. 

This study reports a class of wireless, lightweight, and multifunctional chemical sensors for detection of biomarkers. 

Abstract The ability to predict the efficacy of cancer treatments is a longstanding goal of precision medicine that requires improved understanding of molecular interactions with drugs and the discovery of biomarkers of drug response. Identifying genes whose expression influences drug sensitivity can help address both of these needs, elucidating the molecular pathways involved in drug efficacy and providing potential ways to predict new patients’ response to available therapies. In this study, we integrated cancer type, drug treatment, and survival data with RNA-seq gene expression data from The Cancer Genome Atlas to identify genes and gene sets whose expression levels in patient tumor biopsies are associated with drug-specific patient survival using a log-rank test comparing survival of patients with low vs. high expression for each gene. This analysis was successful in identifying thousands of such gene–drug relationships across 20 drugs in 14 cancers, several of which have been previously implicated in the respective drug’s efficacy. We then clustered significant genes based on their expression patterns across patients and defined gene sets that are more robust predictors of patient outcome, many of which were significantly enriched for target genes of one or more transcription factors, indicating several upstream regulatory mechanisms that may be involved in drug efficacy. We identified a large number of genes and gene sets that were potentially useful as transcript-level biomarkers for predicting drug-specific patient survival outcome. Our gene sets were robust predictors of drug-specific survival and our results included both novel and previously reported findings, suggesting that the drug-specific survival marker genes reported herein warrant further investigation for insights into drug mechanisms and for validation as biomarkers to aid cancer therapy decisions. 

Novel discoveries of biomarkers predictive of drug-specific responses not only play a pivotal role in revealing the drug mechanisms in cancers, but are also critical to personalized medicine. In this study, we identified drug-specific biomarkers by integrating protein expression data, drug treatment data and survival outcome of 7076 patients from The Cancer Genome Atlas (TCGA). We first defined cancer-drug groups, where each cancer-drug group contains patients with the same cancer and treated with the same drug. For each protein, we stratified the patients in each cancer-drug group by high or low expression of the protein, and applied log-rank test to examine whether the stratified patients show significant survival difference. We examined 336 proteins in 98 cancer-drug groups and identified 65 protein-cancer-drug combinations involving 55 unique proteins, where the protein expression levels are predictive of drug-specific survival outcomes. Some of the identified proteins were supported by published literature. Using the gene expression data from TCGA, we found the mRNA expression of ∼11% of the drug-specific proteins also showed significant correlation with drug-specific survival, and most of these drug-specific proteins and their corresponding genes are strongly correlated.